The global Parkinson’s disease treatment market size was estimated at USD 5.65 billion in 2024 and is expected to reach USD 7.58 billion by 2030, growing at a CAGR of 5.04% from 2025 to 2030. The market continues to expand steadily as the global prevalence of Parkinson’s disease (PD) rises, fueled largely by the accelerating aging population and improvements in diagnostic technologies that enable earlier and more accurate detection. Growth is further supported by ongoing advancements in pharmacological interventions, including the development of neuroprotective therapies, RNA-based treatments, and enhanced drug delivery systems designed to overcome challenges associated with traditional oral medications. Increased awareness about PD, supportive government programs, and favorable reimbursement frameworks also help boost treatment uptake across both developed and emerging markets. In addition, a strong pipeline of innovative therapeutics targeting both motor and non-motor symptoms aligns with the expanding patient population, creating new opportunities for market expansion.

These increasing prevalence rates, rising diagnostic volumes, and significant healthcare spending collectively highlight an urgent demand for more effective and advanced treatment solutions. According to the Parkinson’s Foundation (2024), nearly one million people in the U.S. currently live with Parkinson’s disease, and this number is expected to rise to 1.2 million by 2030, reflecting a rapid increase in patient burden. Globally, over 10 million individuals are affected by PD, underscoring the condition’s extensive reach. Each year, an estimated 90,000 new cases are diagnosed in the U.S., with men being 1.5 times more likely to develop the disease than women. Annual U.S. economic costs associated with PD total USD 52 billion, with patients spending approximately USD 2,500 on medications and up to USD 100,000 on surgical procedures such as deep brain stimulation. Studies cited by the Parkinson’s Foundation and The Michael J. Fox Foundation in 2022 further show that prevalence rises significantly with age and varies by region, with higher rates observed in the Rust Belt, reinforcing the growing need for novel therapies and greater research investments.

Strategic initiatives, including new product launches, regulatory approvals, and ongoing clinical research, play a crucial role in shaping the market landscape and accelerating access to advanced PD treatments. A notable example occurred in October 2024, when AbbVie announced U.S. FDA approval for VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion therapy of levodopa for adults with advanced Parkinson’s disease. The approval is based on positive outcomes from the Phase 3 M15-736 study, which demonstrated that VYALEV significantly reduced motor fluctuations and increased “on” time without troublesome dyskinesia compared with standard oral carbidopa/levodopa therapy. This innovation delivers personalized, continuous levodopa dosing, addressing a major challenge faced by patients as oral treatments lose efficacy over time. VYALEV represents a meaningful advancement for individuals who eventually require alternatives to oral formulations but may not yet be candidates for surgical options.

Key Market Trends & Insights:

• North America led the Parkinson’s disease treatment market in 2024, holding a 38.03% revenue share, driven by its high disease prevalence, strong healthcare infrastructure, and substantial investment in research and development. The U.S. market continues to represent the largest share within the region, supported by widespread adoption of advanced therapies and active participation in clinical research.
• The Asia Pacific market is witnessing rapid expansion due to rising healthcare spending, an aging population, and growing awareness of neurological conditions. Countries such as China, India, and Japan are experiencing increasing PD incidence, supporting strong demand for treatment options.
• By drug class, carbidopa-levodopa remained the dominant segment with a 25.12% revenue share in 2024, reflecting its longstanding role as the gold standard for symptom control. Dopamine agonists are expected to show moderate growth due to their efficacy in patients experiencing motor fluctuations or requiring adjunct therapy.
• By distribution channel, retail pharmacies held the largest share at 41.59% in 2024 and are expected to grow fastest because of their accessibility and patient convenience. Online pharmacies are projected to witness moderate growth as patients increasingly adopt home delivery options for chronic medication management.

Order a free sample PDF of the Parkinson’s Disease Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 5.65 Billion
• 2030 Projected Market Size: USD 7.58 Billion
• CAGR (2025-2030): 5.04%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The Parkinson’s disease treatment market is highly competitive, with major pharmaceutical companies leveraging strong product portfolios and continuous innovation to maintain leadership positions. AbbVie, Merck, and GlaxoSmithKline remain at the forefront owing to their established medications such as carbidopa-levodopa formulations and dopamine agonists. These companies are heavily investing in next-generation drug candidates, combination therapies, and patient-tailored treatment solutions. Meanwhile, emerging players are entering the landscape with novel therapeutic mechanisms that challenge existing standards of care, increasing competition. Additionally, mergers, acquisitions, and strategic partnerships are frequently used to expand product pipelines, enhance R&D capabilities, and strengthen global market reach. The market’s growth trajectory is supported by continuous therapeutic advancements, improving patient outcomes, and growing focus on addressing unmet medical needs.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global Parkinson’s disease treatment market is expected to experience steady growth as rising prevalence, aging demographics, and improved diagnostic capabilities continue to expand the patient population. Increasing investment in innovative therapies including continuous infusion systems, neuroprotective agents, and RNA-based treatments is reshaping the treatment landscape and addressing limitations of traditional oral medications. Newly approved therapies, such as AbbVie’s 24-hour levodopa infusion, demonstrate significant clinical progress and highlight the industry’s shift toward personalized, advanced drug delivery solutions. Growing healthcare spending and favorable reimbursement policies further support wider access to both established and emerging treatment options. Regional markets such as North America and Asia Pacific are poised for strong expansion due to high disease burden and increasing awareness of neurological health. Meanwhile, competition is intensifying as leading pharmaceutical companies and new entrants focus on expanding pipelines and accelerating research efforts. Overall, the market is positioned for sustained growth driven by scientific innovation, rising patient needs, and continuous advancements in therapeutic strategies.